Effectiveness and use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease

Jian-Qing Tian [1,†,*], Yu-Hao Lin [1,†], Zhi-Jun Zhang [1], Yi-Ting Peng [2], Jia-Wen Ye [1], Zhi-Yi Wang [1]

[1]Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China

[2]Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China

†These authors have contributed equally to this work and share first authorship

*Correspondence: Jian-Qing Tian, 449256119@qq.com

ABSTRACT

Aim: To explore the association of evidence-based cardiovascular preventive therapies with cardiovascular and renal outcomes in type 2 diabetes (T2DM) patients with established or high risk of atherosclerotic cardiovascular disease (ASCVD).

Methods: In this cohort study, we identified T2DM patients with established or high risk of ASCVD using diagnostic codes from the institutional data of Xiamen Humanity Hospital between 2018 and 2023. Cohort 1 includes participants who were visited between 2018 and 2020, with follow-up until occurrence of an endpoint or December 31, 2020. Participants who were visited between 2018 and 2023 were included in cohort 2. A total of 5,335 patients were included in cohort 1, and 17,320 patients were included in cohort 2. Primary outcomes were hazard ratios (HRs) for the composite of 3-point major adverse cardiovascular event (3-P MACE), hospitalization for heart failure (HHF), and end-stage kidney disease or doubling of serum creatinine level.

Results: Relative to patients' non-use of evidence-based cardiovascular preventive therapies, the use of at least one evidence-based cardiovascular preventive therapy was associated with a lower risk of the 3-P MACE (HR, 0.82; 95% confidence interval [CI], 0.67 to 0.98), HHF (HR, 0.66; 95% CI, 0.47 to 0.92) and end-stage kidney disease or doubling of the serum creatinine level (HR, 0.73; 95% CI, 0.60 to 0.89) after adjustment for potential confounders. From 2018 to 2023, the use of glucagon-like peptide 1 receptor agonists increased from 2.7% to 13.7%;

sodium–glucose cotransporter 2 inhibitors increased from 3.9% to 16.5%; angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers increased from 28.1% to 43.0%; moderate-intensity statins increased from 61.6% to 70.5%; and aspirin increased from 23.7% to 32.9%.

Conclusions: This study demonstrated that T2DM patients with established or high risk of ASCVD might benefit from the use of evidence-based cardiovascular preventive medications with respect to the risk of 3-P MACE, HHF, and end-stage kidney disease or doubling of the serum creatinine level. Despite a modest annual increase in the use of evidence-based cardiovascular preventive medications in T2DM individuals with established or high risk of ASCVD, multiple strategies are needed to overcome barriers to the implementation of evidence-based therapies.

Keywords: type 2 diabetes, atherosclerotic, cardiovascular preventive therapies, cardiovascular and renal outcomes, cohort study

1 Introduction

Type 2 diabetes (T2DM) is a major risk factor for the development of atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of death and long-term complications in T2DM [1]. A systematic review demonstrated that the prevalence of ASCVD in patients with T2DM was nearly 30%, and up to two-thirds of T2DM patients will develop ASCVD during their lifetimes [2,3]. Therefore, there is an urgent need to initiate and intensify secondary preventive to reduce the risk of recurrent cardiovascular events and cardiovascular mortality in patients with T2DM and ASCVD.

Although, the US Food and Drug Administration (FDA) conducted randomized cardiovascular outcome trials (CVOTs) for all glucose–lowering medications in 2008, the cardiovascular benefit of these medications was controversial until 2015. The glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown benefit toward for secondary prevention of ASCVD [4]. Most importantly, large CVOTs of GLP-1 RA and SGLT2i have shown that these drug classes substantially decrease the risk of cardiovascular and renal outcomes [5-11]. What's more, numerous studies have proved the beneficial effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptor blockers (ARBs), statins, and aspirin therapy on cardiovascular and renal outcomes [12-14]. Given these accumulating evidences, the American Diabetes Association (ADA) and the Chinese Diabetes Society recommends the cardio-protective glucose-lowering drug classes (GLP-1 RA and SGLT2i), ACEI/ARB,

statins, and aspirin for comprehensive cardiovascular risk reduction in adults with T2DM and established or high risk of ASCVD [15,16].

Currently, limited evidence is available for the direct comparison of those using versus not using evidence-based cardiovascular preventive therapies (including: GLP-1 RA, SGLT2i, ACEI/ARB, statins, and aspirin) in terms of cardiovascular, hospitalization for heart failure and renal outcomes. Despite these guidelines recommend the GLP-1 RA, SGLT2i, ACEI/ARB, statins, and aspirin for their cardioprotective effects, a degree of therapeutic inertia in clinical practice may be observed for a variety of reasons.

We therefore compared the cardiovascular and renal benefits of use to non-use evidence-based cardiovascular preventive therapies in adults with T2DM and established or high risk of ASCVD. Accurately determining the gaps in evidence-based therapy is essential to disseminate and promote clinical application of guidelines. Thus, we also describe the use of either GLP-1 RA and/or SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin in T2DM individuals with established or high risk of ASCVD during the period 2018 to 2023.

2 Materials and Methods

2.1 Study design and data source

This study was a population-based cohort study. The source population consisted of all outpatients who visited in the Xiamen Humanity Hospital, Fujian Medical University, between January 1, 2018, and December 31, 2023. Informed consent was waived because the study used anonymized patient data. The study protocol was

approved by the Xiamen Humanity Hospital Ethics Committee (no. HAXM-MEC-20240 820-048-01). The study was conducted according to the ethical principles of the Declaration of Helsinki. The trial is registered with Chinese Clinical Trial Registry (ChiCTR) (registration no. ChiCTR2500101328).

2.2 Study population

The study population included adults (age $\geq$ 18 years) between January 1, 2018, and December 31, 2023. Data analysis was performed from January 1, 2024, to December 31, 2024. Disease information was identified using the International Statistical Classification of Diseases, Tenth Revision (ICD-10) (eTable 1). ICD-10 diagnosis codes were utilized to identify T2DM patients at high cardiovascular risk, which include patients with concomitant ASCVD or high risk of ASCVD. Briefly, ASCVD was defined as having a history of coronary artery disease (previous prior myocardial infarction, unstable angina), peripheral arterial disease (amputation due to poor circulation), cerebrovascular disease (stroke, or transient ischemic attack), or any revascularization intervention. Patients at high risk of ASCVD were defined as those aged $\geq$ 55 years with two or more risk factors. Risk factors included obesity (body mass index [BMI] $\geq$ 28 kg/m2), hypertension, smoking, dyslipidemia, and albuminuria [17]. In addition, age, height, weight, and history of smoking were obtained from an electronic medical record. History of hypertension and dyslipidemia were identified by the presence of ICD-10 diagnosis codes. Albuminuria was defined as urine albumin-to-creatinine ratio $\geq$ 30 mg/g. Patients younger than 30 at the time of

initial insulin prescription, with end-stage kidney disease, or limited life expectancy were excluded.

This study population was divided into two cohorts. Participants who were visited between January 1, 2018, and December 31, 2020, were included in cohort 1 (Figure 1). To reduce the effects of prior treatment, we excluded those who had received medication adjustments in the three months preceding enrollment. Participants were followed from 1 day after cohort entry until occurrence of an endpoint or December 31, 2020. Participants were excluded if they discontinued the index drug, died of other causes, or were lost to follow-up. Cohort 1 was divided into group A (non-use of evidence-based cardiovascular preventive therapies) and group B (use at least one evidence-based cardiovascular preventive therapy). Participants who were visited between January 1, 2018, and December 31, 2023, were included in cohort 2 (Figure 2). Patients with longitudinal follow-up may be included in multiple years but only once per year. Within a given year, only patients with at least 1 glucose-lowering medication record were included. If a patient had multiple visits within a specific year, only the last visit was included in the analysis.

2.3 Study Outcomes

We ascertained that the primary outcome was a composite of 3-point major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), hospitalization for heart failure and end-stage kidney disease or doubling of serum creatinine level in cohort 1. Secondary outcomes that were planned in cohort 1 and cohort 2 were specified in the following order: the difference in clinical

characteristics between the use and non-use of evidence-based cardiovascular preventive therapies; the use of evidence-based cardiovascular preventive therapies in T2DM patients with established or high risk of ASCVD. The use of these medications was assessed through the day of the last dispensed prescription within a given year. The prescribed cardioprotective glucose-lowering pharmacotherapy included GLP-1 RA (e.g., semaglutide, dulaglutide, liraglutide, and lixisenatide) and SGLT2i (e.g., empagliflozin, dapagliflozin, and canagliflozin). Prescribed blood pressure-lowering pharmacotherapy included ACEI (e.g., captopril, benazepril, and so on), ARB (e.g., valsartan, irbesartan, and so on), and statins (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin).

2.4 Covariates

Demographic characteristics, such as age and sex were described. Clinical characteristics included glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and BMI. For patients with multiple measurements within a given year, only the last one was used. The co-morbidities (heart failure, atrial fibrillation, hypertension, dyslipidemia, and nonalcoholic fatty liver disease) and diabetes chronic complications (retinopathy, neuropathy, and nephropathy) were identified using the ICD-10 code. Concomitant use of oral anti-diabetic, antihypertensive, and lipid-lowering medications was assessed.

2.5 Composite Score for Evidence-based Therapy

Evidence-based therapy was defined as the use of either a GLP-1 RA and/or SGLT2i,

either an ACEI or ARB, a moderate-intensity statins, and an aspirin. Although high-dose statins are important to prevent cardiovascular events, it is intolerable for most of Chinese populations. Therefore, moderate-intensity statins are recommended as the first choice lipid-lowering drugs by the Endocrinology and Metabolism Physician Branch of the Chinese Medical Doctor Association [18]. Patients in this cohort were deemed to meet the criteria for all four components and were assigned a composite score ranging from 0 to 4, indicating the number of evidence-based therapies prescribed.

2.6 Statistical Analysis

Demographic and clinical characteristics, co-morbidities, and concomitant medications were presented as with means ± standard deviations (SDs) for continuous variables and frequency/percentages for categorical variables. The number and proportion of patients with T2DM and established or high risk of ASCVD who received GLP-1 RA and/or SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin were evaluated annually. Treatment effect was estimated using hazard ratios (HRs) from a Cox regression model. Subgroup analyses were performed by sex, the presence of ASCVD or high risk of ASCVD, the presence of heart failure, and the presence of chronic kidney disease. All data where necessary were conducted to calculate 95% confidence interval (CI). Statistical comparisons baseline characteristics between the different groups were using the independent-sample t test for continuous variables and $\chi2$ test or Fisher's exact test for categorical variables.

Two-sided P values <$\square$0.05 were considered statistically significant. All analyses were performed using R version 4.4.2 (R Foundation).

3. Results

3.1 Study Participants

We identified 5,335 patients in cohort 1 (2,793 patients with a dual diagnosis of T2DM and ASCVD and 2,524 patients with T2DM and high risk of ASCVD) and 17,320 patients in cohort 2 (8,418 patients with a dual diagnosis of T2DM and ASCVD and 8,902 patients with T2DM and high risk of ASCVD).

Among 5,335 patients in cohort 1, a total of 2,275 patients were assigned to the group A and 2,610 were assigned to the group B. Compared with the group A, patients in the group B were younger (mean [SD]: 65.4 [10.1] years vs 66.8 [10.1] years), more likely to be male (57.5% vs 55.2%), with a lower proportion of second-generation sulfonylurea use (22.4% vs 30.3%) and more common with Urban employee medical insurance (25.8% vs 24.7%). There were differences between group A and group B in clinical characteristics (e.g., 2,275 patients in group A vs 2,610 patients in group B: initiation of SGLT-2i or GLP-1 RAs, 1.6% vs 3.1%; coronary artery disease, 71.2% vs 74.6%; cerebrovascular disease, 20.1% vs 23.3%; heart failure, 30.6% vs 35.8%; CKD stage 3, 18.7% vs 21.5%; mean [SD] Charlson Comorbidity Index score, 4.0 [2.7] vs 4.4 [2.9]) (Table 1).

3.2 Primary Outcomes

A 3-point major adverse cardiovascular event occurred in 228 of 2,610 patients (8.7%)

in the group B (use of at least one evidence-based cardiovascular preventive therapy) and in 237 of 2725 patients (8.7%) in the group A (non-use of evidence-based cardiovascular preventive therapies) (hazard ratio, 0.96; 95% confidence interval [CI], 0.80 to 1.16; P=0.69). Hospitalization for heart failure occurred in 79 of 2,610 patients (3.0%) in the group B and in 103 of 2,725 patients (3.8%) in the group A (hazard ratio, 0.84; 95% CI, 0.62 to 1.12; P=0.23). With respect to the end-stage kidney disease or doubling of the serum creatinine level, the hazard ratio (group B vs group A) was 0.90 (95% CI, 0.75 to 1.09) (Table 2). After adjustment for potential confounders, patients in the group B showed a significant decreased risk of 3-P MACE (hazard ratio, 0.82; 95% CI, 0.67 to 0.98; P=0.036), HHF (hazard ratio, 0.66; 95% CI, 0.47 to 0.92; P<0.01), and end-stage kidney disease or doubling of the serum creatinine level (hazard ratio, 0.73; 95% CI, 0.60 to 0.89; P<0.01) compared with the group A (Table 2). Subgroup analyses did not show a difference in the risk of 3-point MACE, HHF and end-stage kidney disease or doubling of serum creatinine level between the two groups (eTable 2).

3.3 Use Ratios

Overall, the utilization of glucose-lowering drugs with documented cardiovascular benefits was low; however, the rate increased annually from 2018 to 2023 (GLP-1 RA: from 2.7% [73 of 2,720] to 13.7% [439 of 3,200]; SGLT2i: from 3.9% [107 of 2720]

to 16.5% [529 of 3200]). Combined, the percentage of patients with T2DM and established or high risk of ASCVD taking either agent increased from 5.7% (156 of 2,720) in 2018 to 21.0% (671 of 3200) in 2023 (Figure 3). Metformin use was essentially unchanged over this time (61.3% [1667 of 2,720] in 2018 vs 60.8% [1,945 of 3,200] in 2023). Use of noncardiovascular glucose-lowering agents exhibited a variable decline, including alpha-glucosidase inhibitors (30.1% [818 of 2,720] to 22.2% [709 of 3,200]) and dipeptidyl peptidase-4 inhibitors (DPP-4i) (25.5% [694 of 2,720] to 20.8% [665 of 3,200]), although these medications remained more commonly used than SGLT2i or GLP-1 RAs through 2023 (eFigure 1). Of the antihypertensive medications, the use of ACEI/ARB was increased from 28.1% [764 of 2,720] to 43.0% [1,377 of 3,200], while the use of calcium channel blockers was decreased (44.2% [1,202 of 2,720] to 41.8% [1,336 of 3,200]) from 2018 to 2023 (eFigure 2). The use of moderate-intensity statins (61.6% [1,676 of 2,720] to 70.5% [2,255 of 3,200]) and aspirin (23.7% [645 of 2,720] to 32.9% [1,053 of 3,200]) pharmacotherapy variably increased (eFigure 3 and Fig 3). In patients with high risk of ASCVD, GLP-1 RA, SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin showed lower usage rates than patients with ASCVD (eFigure 4).

3.4 Evidence-based Therapy

Compared with the overall cohort, patients prescribed GLP-1RA or SGLT2i were younger (mean age: GLP-1 RA: 61.1 years; SGLT2i: 63.0 years; overall: 66.3 years), had lower prevalence of heart failure (GLP-1 RA: 26.4%; SGLT2i: 21.4%; overall:

32.3%), had higher prevalence of dyslipidemia (GLP-1 RA: 87.2%; SGLT2i: 86.8%; overall: 81.5%), had fewer medical comorbidities (mean Charlson comorbidity index score: GLP-1 RA: 3.8; SGLT2i: 3.7; overall: 4.0) and had a lower percentage of patients with HbA1c < 7% (GLP-1 RA: 33.5%; SGLT2i: 36.6%; overall: 41.1%). Patients who prescribed a GLP-1 RA had higher prevalence of diabetes chronic complications (retinopathy: 16.1% vs 9.9%; neuropathy: 40.9% vs 27.6%) compared with the overall cohort (Table 3). The demographics and clinical characteristic of patients prescribed an ACEI or ARB, moderate-intensity statin and aspirin were displayed in Table 3.

4 Discussion

In our cohort of patients with T2DM and established or high risk of ASCVD, we demonstrated that the use of evidence-based cardiovascular preventive therapies was associated with a lower risk of 3-point MACE, HHF and end-stage kidney disease or doubling of serum creatinine level relative to non-use. And our study suggested that the overall usage of evidence-based cardiovascular preventive therapies between 2018 and 2023. The overall antihyperglycemic agents with proven cardiovascular benefits use was 7.6% for GLP-1 RA, and 10.5% for SGLT2i. The utilization rates were 35.5% for ACEI/ARB, 66.3% for moderate-intensity statins, and 28.7% for aspirin. Further, approximately half of patients received no evidence-based cardiovascular benefit medication.

To our knowledge, this study was one of the few to date to compare the cardiovascular and renal effectiveness of using or not-using evidence-based

cardiovascular preventive therapies. Consistent with a meta-analysis of cardiovascular outcome trials, we found that benefits of GLP-1 RA, SGLT2i, ACEI/ARB, statins, and aspirin were observed for the outcomes of 3-point MACE, HHF and end-stage kidney disease or doubling of serum creatinine level [19-23].

The baseline of clinical characteristics was different between those using and not using evidence-based cardiovascular preventive therapies, and this might account for the failure to observe a difference in cardiovascular outcomes between the two groups. Consistent with a large cohort study, we observed that benefits for the outcomes of 3-point MACE, HHF, and end-stage kidney disease or doubling of serum creatinine level were significant difference between the two groups after adjusting for covariates [24].

Although both GLP-1 RA, SGLT-2i, ACEI/ARB, statins and aspirin have demonstrated cardiovascular benefits, the usage of these drugs is still low in the real-world [25,26]. Our finding suggested that the overall utilization of evidence-based cardiovascular preventive therapies was lower than expected, particularly for GLP-1 RA and SGLT2i. The findings that 14.0% of patients in our study prescribed either a GLP-1 RA or SGLT2i (GLP-1 RA: 7.6%, SGLT2i: 10.5%) are consistent with those of recent studies conducted in the US and Belgian [27-29]. Fortunately, our study found that the use of both GLP-1 RA and SGLT2i increased gradually from 2018 to 2023. However, as recently as 2023, two glucose-lowering therapies without proven cardiovascular benefit, namely alpha-glucosidase inhibitors and DPP-4i, continue to be used more frequently than either GLP-1 RA or SGLT2i.

Addressing these gaps in optimal pharmacotherapy is pivotal to improve patient outcomes. Reasons for continued underuse of these evidence-based therapies are likely multifactorial, and include the guidelines update, the relatively higher cost and out-of-pocket cost of new therapies, as well as clinical inertia. As we known, GLP-1 RA and SGLT2i both have demonstrated substantial benefits on major adverse cardiovascular events in those with T2DM and ASCVD [20,30]. Based on these data, the ADA has recommended GLP-1 RA and SGLT2i as first-line agents for patients with T2DM and ASCVD after metformin since 2019 [31]. In 2023, the ADA recommended that clinicians consider prescribing GLP-1 RA and SGLT2i prior to metformin for patients with T2DM and established or high risk of ASCVD [32]. In the wake of these updates, the use of GLP-1 RA and SGLT2i both slightly increased from 2018 through 2019, followed by a more than 3-fold from 2019 to 2023.

Despite the room for improvement, our findings support cautious optimism around the uptake of these agents in clinical practice. The use of GLP-1 RA rates doubled from 2020 through 2021, when the semaglutide was covered by health insurance in China. A similar trend was observed for SGLT2i, when the empagliflozin and dapagliflozin was covered by health insurance in 2020, the usage rates of these drugs doubled from 2019 to 2020. The rate of urban employee medical insurance was higher among those using evidence-based cardiovascular preventive therapies compared with those not using.

Therapeutic inertia within the realm of CVD prevention is a well-established barrier to widespread and consistent implementation of novel pharmacotherapeutic advances

[33]. Herein, we observed slightly higher HbA1c levels and had a lower percentage of patients achieved HbA1c < 7% among those treated with GLP-1 RA and SGLT2i. These agents remained to be used less frequently than metformin or alpha-glucosidase inhibitors. This could imply that GLP-1 RA and SGLT2i were not considered as first-line therapeutic in T2DM individuals with high cardiovascular risk by clinicians.

There are several strengths and limitations to this study. The primary strength of this study is that it was the first to compare the cardiovascular and renal effectiveness of using or not-using evidence-based cardiovascular preventive therapies. And we further confirmed the benefits of GLP-1 RA, SGLT-2i, ACEI/ARB, statins, and aspirin on the cardiovascular and renal outcomes for patients with T2DM and established or high risk of ASCVD. Second, we identified the rates of use of the evidence-based cardiovascular preventive therapies among T2DM patients with established or high risk of ASCVD. Additionally, we explored the possible reasons for the underuse of these evidence-based therapies. However, there are some limitations in this study. Firstly, given the nature of our study, it cannot prove causality or completely rule out residual confounding. We do our utmost to adjust for any possible confounding factors that may affect the primary outcomes. Secondly, our study sample consisting almost entirely of participants of Asian ethnicity, and whether the results can be extrapolated to non-Asian populations remains uncertain. Finally, our findings suggest that treatment discontinuation is common. However, the reason for patients switching from cardiovascular evidence-based therapies to other noncardiovascular agents was not illuminated in this study.

5 Conclusion

In conclusion, it is particularly concerning that relative to cardiovascular evidence-based therapies (GLP-1 RA, SGLT-2i, ACEI/ARB, statins, and aspirin), was associated with a lower risk of the 3-point MACE, HHF and end-stage kidney disease or doubling of serum creatinine level outcome in T2DM patients with ASCVD or high risk of ASCVD after adjusting for covariates. Despite estimates of evidence-based therapy prescription are considerably lower than expected, the rates of cardiovascular evidence-based therapies increased annually from 2018 to 2023. To continue this momentum, creative implementation science approaches will be necessary to further increase the use of these safe and effective medications in T2DM individuals with established or high risk of ASCVD.

Acknowledgements

We would like to thank Natural Science Foundation of Xiamen Province, China for funding this work.

Funding

This work was supported by the Medical and Health Guidance Projects of Xiamen, China (Grant No.3502Z20224ZD1106).

References

1. Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism. Oct 2021;123:154838. doi:10.1016/j.metabol.2021.154838

2. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. Jun 8 2018;17(1):83. doi:10.1186/s12933-018-0728-6.

3. Bancks MP, Ning H, Allen NB, et al. Long-term Absolute Risk for Cardiovascular Disease Stratified by Fasting Glucose Level. Diabetes Care. Mar 2019;42(3):457-465. doi:10.2337/dc18-1773.

4. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. Jul 17 2021;398(10296):262-276. doi:10.1016/s0140-6736(21)00536-5.

5. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. Jul 13 2019;394(10193):121-130. doi:10.1016/s0140-6736(19)31149-3.

6. Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. Aug 29 2019;381(9):841-851. doi:10.1056/NEJMoa1901118.

7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. Nov 10 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141.

8. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. Jul 28 2016;375(4):311-22. doi:10.1056/NEJMoa1603827.

9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. Aug 17 2017;377(7):644-657. doi:10.1056/NEJMoa1611925.

10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. Jan 24 2019;380(4):347-357. doi:10.1056/NEJMoa1812389.

11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and

Mortality in Type 2 Diabetes. N Engl J Med. Nov 26 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720.

12. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. Mar 2022;145(9):e722-e759. doi:10.1161/cir.0000000000001040

13. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. Sep 7 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484

14. Peikert A, Vaduganathan M, Mc Causland F, et al. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail. May 2022;24(5):794-803. doi:10.1002/ejhf.2450

15. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. Jan 1 2025;48(Supplement_1):S207-s238. doi:10.2337/dc25-S010

16. Society. CD. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)]. Chin J Diabetes Mellitus. April 2021;13(4):315-409.

17. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. Jan 1 2025;48(Supplement_1):S181-s206. doi:10.2337/dc25-S009

18. Xiao Y, Yu B, Chao C, et al. Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition). J Transl Int Med. Sep 2024;12(4):325-343. doi:10.2478/jtim-2024-0014

19. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. Oct 2019;7(10):776-785. doi:10.1016/s2213-8587(19)30249-9

20. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. Jan 5 2019;393(10166):31-39. doi:10.1016/s0140-6736(18)32590-x

21. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure-lowering treatment for prevention of

major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol. Sep 2022;10(9):645-654. doi:10.1016/s2213-8587(22)00172-3

22. Soroush N, Nekouei Shahraki M, Mohammadi Jouabadi S, et al. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. Sep 2024;34(9):2021-2033. doi:10.1016/j.numecd.2024.04.015

23. Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. Jun 3 2019;18(1):70. doi:10.1186/s12933-019-0875-4

24. Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. Aug 16 2018;379(7):633-644. doi:10.1056/NEJMoa1800256

25. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. May 12 2020;141(19):e779-e806. doi:10.1161/cir.0000000000000766

26. Leino AD, Dorsch MP, Lester CA. Changes in Statin Use Among U.S. Adults With Diabetes: A Population-Based Analysis of NHANES 2011-2018. Diabetes Care. Dec 2020;43(12):3110-3112. doi:10.2337/dc20-1481

27. King A, Tan X, Dhopeshwarkar N, et al. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Res Care. Oct 4 2024;12(5)doi:10.1136/bmjdrc-2024-004431

28. Raat W, Mamouris P, Mathieu C, Goderis G, Vaes B. Trends in type 2 diabetes medication use and guideline adherence in Belgian primary care (2019-2023). Prim Care Diabetes. Oct 31 2024;doi:10.1016/j.pcd.2024.10.007

29. Shin JI, Xu Y, Chang AR, et al. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. J Am Coll Cardiol. Aug 20 2024;84(8):683-693. doi:10.1016/j.jacc.2024.05.057

30. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. Apr 23 2019;139(17):2022-2031. doi:10.1161/circulationaha.118.038868

31. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. Jan 2019;42(Suppl 1):S103-s123. doi:10.2337/dc19-S010

32. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. Jan 1 2023;46(Suppl 1):S140-s157. doi:10.2337/dc23-S009

33. Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. J Am Coll Cardiol. Oct 1 2019;74(13):1728-1731. doi:10.1016/j.jacc.2019.08.014

Table 1 Patient characteristics by overall evidence-based composite score (Cohort 1).

Patient characteristics	Evidence-based therapy score, % (95% CI)	
	0 (n=2725)	1-4 (n=2610)
Age, mean (SD) [95% CI], y	66.8 (10.1) [66.7-66.9]	65.4 (10.1) [65.3-65.5]
Sex		
Male	55.2 (53.3-57.1)	57.5 (55.6-59.5)
Female	44.8 (42.9-46.8)	42.5 (40.6-44.5)
Lifestyle factors		
Obesity	46.2 (44.2-48.1)	48.0 (46.1-49.9)
Smoking	22.9 (21.2-24.5)	23.9 (22.3-25.6)
Diabetes-related conditions		
Retinopathy	7.2 (6.2-8.2)	11.4 (10.2-12.6)
Neuropathy	22.6 (21.0-24.2)	28.6 (26.9-30.4)
Nephropathy	27.5 (25.7-29.2)	31.9 (30.1-34.8)
Diabetes treatment		
Initiation of SGLT-2i or GLP-1 RAs	1.6 (1.1-2.1)	3.1 (2.4-3.8)
Concurrent metformin	63.1 (61.3-64.9)	62.3 (60.5-64.2)
Concurrent second-generation sulfonylurea	30.3 (28.6-32.0)	22.4 (20.8-24.0)
ASCVD (n=2793)		
Coronary artery disease	71.2 (69.5-72.9)	74.6 (72.9-76.3)
Cerebrovascular disease	20.1 (18.6-21.6)	23.3 (21.7-24.9)
Peripheral arterial disease	45.4 (43.5-47.3)	48.7 (46.8-50.6)
Comorbidities		
Heart failure	30.6 (28.9-32.4)	35.8 (34.0-37.7)
Atrial fibrillation	20.4 (18.9-21.9)	19.7 (18.2-21.2)
Hypertension	81.3 (79.8-82.8)	88.8 (87.6-90.0)
Hyperlipidemia	75.8 (74.2-77.4)	86.7 (85.4-88.0)
CKD stage 3	18.7 (17.2-20.2)	21.5 (19.9-23.1)
Nonalcoholic fatty liver disease	16.7 (15.3-18.1)	17.1 (15.6-18.6)
Charlson Comorbidity Index score, mean (SD) [95% CI]	4.0 (2.7) [3.9-4.1]	4.4 (2.9) [4.3-4.5]
Laboratory values, mean (SD)		
HbA1c, %	7.8 (1.9) [7.7-7.8]	7.8 (2.1) [7.7-7.9]

LDL-C, mmol/L	2.8 (1.0) [2.8-2.8]	2.9 (0.9) [2.9-2.9]
HbA1c < 7%	40.1 (38.3-42.0)	39.7 (37.8-41.6)
LDL-C < 1.8	14.4 (13.1-15.7)	13.9 (12.6-15.2)
LDL-C < 1.4	4.0 (3.3-4.7)	4.1 (3.3-4.9)
Insurance coverage		
Urban Employee	24.7 (23.1-26.3)	25.8 (24.1-27.5)
Urban Resident	56.1 (54.2-58.0)	51.4 (49.5-53.3)
Self-pay	5.1 (4.3-5.9)	6.2 (5.3-7.1)
Missing	14.1 (12.8-15.4)	16.6 (15.2-18.0)

Notes: SGLT-2i, sodium-glucose cotransporter-2 inhibitors; GLP-1 RA, glucagon-like peptide-1 receptor agonists; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.

Table 2. Treatment effect estimates for evidence-based therapies.

	Total No. of events (%)		Unadjusted		Model 1	
			Group B vs Group A			
	Group B	Group A			HR (95% CI)	*p*
Outcome	(n=2610)	(n=2725)	HR (95% CI)	*p*		
3-P MACE	228 (8.7)	237 (8.7)	0.96 (0.80-1.16)	0.69	0.82 (0.67-0.98)	0.036
HHF	79 (3.0)	103 (3.8)	0.84 (0.62-1.12)	0.23	0.66 (0.47-0.92)	<0.01
End-stage kidney disease, doubling of serum creatinine level	198 (7.6)	226 (8.3)	0.90 (0.75-1.09)	0.29	0.73 (0.60-0.89)	<0.01

Notes: 3-P MACE, 3-point major adverse cardiovascular event; HHF, hospitalization for heart failure; HR, hazard ratio.

Model 1: Adjusted for sex, age, smoke, BMI, HbA1c, LDL-C, history of diseases including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, hypertension, and hyperlipidemia.

Table 3. Patient characteristics at baseline by individual evident-based therapies (Cohort 2).

Patient characteristics	Patients, % (95% CI)					
		Therapy prescription			moderate-inte	
	Overall	GLP-1 RA	SGLT-2i	ACEI/ARB	nsity statin	Aspirin
	(N = 17320)	(N = 1321)	(N = 1814)	(N = 6157)	(N = 11476)	(N = 4965)
Age, mean (SD) [95% CI], y	66.3 (10.8)	61.1 (11.2)	63.0 (8.4)	67.0 (10.1)	66.2 (10.2)	65.4 (10.0)
	[66.2-66.3]	[60.5-61.7]	[62.6-63.4]	[66.7-67.3]	[66.0-66.4]	[65.1-65.7]
Sex						
Male	56.1	58.9	53.8	56.8	56.9	63.3
	(55.4-56.8)	(56.2-61.6)	(51.5-56.1)	(55.6-58.0)	(56.0-57.8)	(62.0-64.6)
Female	43.9	41.1	46.2	43.2	43.1	36.7
	(43.2-44.6)	(38.4-43.8)	(43.9-48.5)	(42.0-44.4)	(42.2-44.0)	(35.4-38.0)
Lifestyle factors						
Obesity	47.9	51.6	49.9	45.8	48.3	48.5
	(47.2-48.6)	(48.9-54.3)	(47.6-52.2)	(44.6-47.1)	(47.4-49.2)	(47.1-49.9)
Smoking	23.0	22.4	20.2	23.8	25.9	24.3
	(22.4-23.6)	(20.2-24.6)	(18.4-22.1)	(22.7-24.9)	(25.1-26.7)	(23.1-25.5)
Diabetes-related conditions						
Retinopathy	9.9	16.1	11.7	11.2	12.8	13.4
	(9.5-10.3)	(14.1-79.2)	(10.2-13.2)	(10.4-12.1)	(12.2-13.4)	(12.5-14.3)
Neuropathy	27.6	40.9	29.9	29.3	29.7	31.7
	(26.9-28.3)	(38.2-43.6)	(27.8-32.0)	(28.2-30.4)	(28.9-30.5)	(30.4-33.0)
Nephropathy	21.8	24.4	20.9	23.4	24.3	25.6
	(21.1-22.5)	(21.7-27.1)	(28.6-23.2)	(22.2-24.6)	(23.4-25.2)	(24.2-27.0)
ASCVD (n=8418)						
Coronary artery disease	72.0	68.5	71.6	72.2	78.3	73.8
	(71.3-72.7)	(66.0-71.0)	(69.5-73.7)	(71.1-73.3)	(77.5-79.1)	(72.6-75.0)
Cerebrovascular disease	21.7	17.8	18.1	20.1	25.1	24.4
	(21.1-22.3)	(15.7-19.9)	(16.3-19.9)	(19.1-21.1)	(24.3-25.9)	(23.2-25.6)
Peripheral arterial disease	47.9	51.5	49.9	50.2	49.0	50.3
	(47.1-48.6)	(48.4-54.2)	(47.6-52.2)	(49.0-51.4)	(48.1-49.9)	(48.9-51.7)
Comorbidities						
Heart failure	32.3	26.4	21.4	31.2	39.6	38.7
	(31.6-33.0)	(11.6-15.2)	(7.1-9.7)	(10.4-12.0)	(9.1-10.1)	(7.9-9.5)

Atrial fibrillation	19.8 (19.2-20.4)	15.6 (42.9-48.3)	16.0 (24.0-28.0)	20.9 (21.9-23.9)	20.7 (22.9-24.5)	21.7 (22.5-24.9)
Hypertension	84.4 (83.9-85.0)	85.6 (83.7-87.5)	84.2 (82.5-85.9)	88.1 (87.3-88.9)	86.1 (85.5-86.7)	87.3 (86.4-88.2)
Hyperlipidemia	81.5 (80.9-82.0)	87.2 (85.4-89.0)	86.8 (85.2-88.4)	84.2 (83.3-85.1)	90.2 (89.7-90.7)	89.5 (88.6-90.4)
CKD stage 3	19.2 (18.6-19.8)	21.4 (19.2-23.6)	18.7 (16.9-20.5)	21.6 (20.6-22.6)	22.1 (21.3-22.9)	23.2 (22.0-24.4)
Nonalcoholic fatty liver disease	17.4 (16.9-18.0)	25.6 (23.2-28.0)	23.2 (21.3-25.1)	19.2 (18.2-20.2)	21.3 (20.6-22.0)	18.5 (17.4-19.6)
Charlson Comorbidity Index score, mean (SD) [95% CI]	4.0 (2.6) [3.9-4.0]	3.9 (2.5) [3.8-4.0]	3.7 (2.4) (3.6-3.8)	4.2 (2.7) (4.1-4.3)	4.4 (2.9) (4.3-4.5)	4.5 (2.8) (4.4-4.6)
Laboratory values, mean (SD)						
HbA1c, %	7.7 (1.8) [7.7-7.7]	8.2 (2.0) [8.1-8.3]	8.1 (1.8) [8.0-8.2]	7.7 (1.8) [7.7-7.7]	7.8 (1.8) [7.8-7.8]	8.0 (1.9) [7.9-8.1]
LDL-C, mmol/L	2.8 (1.0) [2.8-2.8]	2.6 (0.9) [2.6-2.6]	2.7 (0.9) [2.7-2.7]	2.7 (1.0) [2.7-2.7]	2.7 (1.0) [2.7-2.7]	2.7 (1.0) [2.7-2.7]
HbA1c < 7%	41.1 (40.4-41.8)	39.5 (36.9-42.1)	40.2 (37.9-42.5)	41.7 (40.5-42.9)	40.3 (39.4-41.2)	40.8 (39.4-42.2)
LDL-C < 1.8	14.6 (14.1-15.1)	16.0 (14.0-18.0)	15.9 (14.2-17.6)	15.8 (14.9-16.7)	16.4 (15.7-17.1)	15.7 (14.7-16.7)
LDL-C < 1.4	4.3 (4.0-4.6)	4.8 (3.6-6.0)	4.6 (3.6-5.6)	4.7 (4.2-5.2)	5.3 (4.9-5.7)	4.7 (4.1-5.3)
Insurance coverage						
Urban Employee	26.6 (26.0-27.3)	31.6 (29.1-34.1)	31.2 (29.1-33.3)	29.7 (28.6-30.8)	27.2 (26.4-28.0)	27.4 (26.2-28.6)
Urban Resident	51.2 (50.4-51.9)	45.4 (42.7-48.1)	47.2 (44.9-49.5)	49.3 (48.1-50.5)	49.8 (48.9-50.7)	50.1 (48.7-51.5)
Self-pay	5.9 (5.5-6.2)	4.1 (3.0-5.2)	4.4 (3.5-5.3)	4.6 (4.1-5.1)	4.5 (4.1-4.9)	5.1 (4.5-5.7)
Missing	16.4 (15.8-16.9)	18.9 (16.8-21.0)	17.2 (15.5-18.9)	16.4 (15.5-17.3)	18.5 (17.8-19.2)	17.4 (16.3-18.5)

Notes: GLP-1 RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; ACEI, angiotensin-converting enzyme inhibitors; ARB,

angiotensin-receptor blockers; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic

kidney disease; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein

cholesterol; SD, standard deviation.

Figure 1. Flow Diagram for Cohort 1.

Notes: T2DM, type 2 diabetes mellitus; ASCVD, atherosclerotic cardiovascular disease.

Figure 2. Flow Diagram for Cohort 2.

Notes: T2DM, type 2 diabetes mellitus; ASCVD, atherosclerotic cardiovascular disease.

Figure 3. Trends in evidence-based therapy use among T2DM patients with established or high risk of ASCVD.

Notes: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; GLP-1 RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2 inhibitors.